G K Ellis

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012
    Georgiana K Ellis
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Seattle, WA 98109 1023, USA
    J Clin Oncol 29:1014-21. 2011
  2. ncbi Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients
    G K Ellis
    Division of Oncology, University of Washington, Seattle 98195 6043, USA
    J Clin Oncol 17:1407-12. 1999
  3. ncbi Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
    Georgiana K Ellis
    Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA, 98109 1023, USA
    Breast Cancer Res Treat 118:81-7. 2009
  4. ncbi Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
    Georgiana K Ellis
    Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:4875-82. 2008
  5. ncbi Dose-dense anthracycline-based chemotherapy for node-positive breast cancer
    Georgiana K Ellis
    Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA
    J Clin Oncol 20:3637-43. 2002
  6. ncbi Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
    R B Livingston
    Division of Oncology, University of Washington, Seattle 98195 6043, USA
    J Clin Oncol 15:1395-400. 1997
  7. ncbi Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
  8. ncbi Potential of chemotherapy-herb interactions in adult cancer patients
    Jeannine S McCune
    University of Washington, Seattle, WA 98195, USA
    Support Care Cancer 12:454-62. 2004
  9. ncbi Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
  10. ncbi [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002

Detail Information

Publications19

  1. ncbi Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012
    Georgiana K Ellis
    Seattle Cancer Care Alliance, 825 Eastlake Ave East, Seattle, WA 98109 1023, USA
    J Clin Oncol 29:1014-21. 2011
    ..All patients had subsequent weekly paclitaxel for 12 weeks before surgery...
  2. ncbi Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients
    G K Ellis
    Division of Oncology, University of Washington, Seattle 98195 6043, USA
    J Clin Oncol 17:1407-12. 1999
    ..All patients received scheduled support with granulocyte colony-stimulating factor (G-CSF; filgrastim). Tumor response, toxicity, time to progression (TTP), and survival were assessed...
  3. ncbi Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study
    Georgiana K Ellis
    Seattle Cancer Care Alliance, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA, 98109 1023, USA
    Breast Cancer Res Treat 118:81-7. 2009
    ..Most increases were statistically significant (P < 0.05). Twice-yearly administration of denosumab, regardless of patient subgroup or skeletal site, resulted in consistent increases in BMD versus placebo at 12 and 24 months...
  4. ncbi Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer
    Georgiana K Ellis
    Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:4875-82. 2008
    ..We investigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-kappaB ligand, to protect against aromatase inhibitor-induced bone loss...
  5. ncbi Dose-dense anthracycline-based chemotherapy for node-positive breast cancer
    Georgiana K Ellis
    Division of Medical Oncology, University of Washington, and Fred Hutchinson Cancer Research, Seattle, WA
    J Clin Oncol 20:3637-43. 2002
    ..We studied a dose-dense combination of doxorubicin and cyclophosphamide, with or without fluorouracil, as adjuvant therapy...
  6. ncbi Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer
    R B Livingston
    Division of Oncology, University of Washington, Seattle 98195 6043, USA
    J Clin Oncol 15:1395-400. 1997
    ..Objective tumor response, DDI, and toxicity were assessed, as well as time to progression (TTP) and survival...
  7. ncbi Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer
    Lisa K Dunnwald
    Department of Bioengineering, Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    J Clin Oncol 26:4449-57. 2008
    ..Serial positron emission tomography (PET) has been shown to predict pathologic response in this setting. We evaluated serial quantitative PET tumor blood flow (BF) and metabolism as in vivo measurements to predict patient outcome...
  8. ncbi Potential of chemotherapy-herb interactions in adult cancer patients
    Jeannine S McCune
    University of Washington, Seattle, WA 98195, USA
    Support Care Cancer 12:454-62. 2004
    ....
  9. ncbi Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, Washington 98195, USA
    J Nucl Med 44:1806-14. 2003
    ..To characterize in vivo tumor biology in patients with LABC, we performed serial measurements of blood flow and glucose metabolism in LABC patients over the course of neoadjuvant chemotherapy and compared measurements with response...
  10. ncbi [Tc-99m]-sestamibi uptake and washout in locally advanced breast cancer are correlated with tumor blood flow
    David A Mankoff
    Division of Nuclear Medicine, University of Washington, Seattle, WA, USA
    Nucl Med Biol 29:719-27. 2002
    ..To determine the influence of breast tumor blood flow on MIBI kinetics, we compared MIBI uptake and washout to [O-15]-water PET estimates of blood flow in patients with locally advanced breast cancer...
  11. ncbi Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy
    David A Mankoff
    Division of Nuclear Medicine, Box 346113, University of Washington, 1959 E Pacific Street, Seattle, WA 98195, USA
    J Nucl Med 43:500-9. 2002
    ....
  12. ncbi Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC)
    Jennifer R Bellon
    Department of Radiation Oncology, University of Washington Medical Center, Seattle, WA, USA
    Am J Clin Oncol 27:407-10. 2004
    ..FDG-PET appears to be a useful noninvasive modality to detect IM metastases in LABC. Pathologic verification in a prospective study is necessary to confirm these findings...
  13. ncbi Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer
    Hannah M Linden
    Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    J Clin Oncol 24:2793-9. 2006
    ..We tested the ability of FES-PET imaging to predict response to salvage hormonal treatment in heavily pretreated metastatic breast cancer patients, predominantly treated with aromatase inhibitors...
  14. ncbi Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)
    Jennifer M Specht
    Division of Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, 825 Eastlake Avenue E, G3 200, Seattle, WA 98109, USA
    Breast Cancer Res Treat 105:87-94. 2007
    ..Our goal was to evaluate the prognostic power of serial FDG PET in BD breast cancer patients undergoing treatment...
  15. ncbi 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer
    W B Eubank
    Department of Radiology, University of Washington School of Medicine, Seattle, USA
    J Clin Oncol 19:3516-23. 2001
    ....
  16. ncbi Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival
    Lisa K Dunnwald
    Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, Washington 98195, USA
    Cancer 103:680-8. 2005
    ..Given the association between MIBI uptake and tumor blood flow, this prognostic capability may be related to retained tumor vascularity after treatment...
  17. ncbi HER-2 testing in breast cancer using parallel tissue-based methods
    Hadi Yaziji
    PhenoPath Laboratories, Seattle, Wash 98103, USA
    JAMA 291:1972-7. 2004
    ..Successful quality control and quality assurance programs are a prerequisite for such approaches...
  18. ncbi Myalgias and arthralgias associated with paclitaxel
    Julie A Garrison
    Department of Pharmacy, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, USA
    Oncology (Williston Park) 17:271-7; discussion 281-2, 286-8. 2003
    ....
  19. ncbi Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma
    Dianne Georgian-Smith
    Department of Radiology, Breast Imaging, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Breast J 9:316-8. 2003
    ..We advocate routine screening and physical examination in all patients, even in the presence of perplexing clinical symptoms...